# Oruka Therapeutics Posts $0.63 Q3 GAAP Loss Per Share, Matching Estimates

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/53412
Published: 2026-11-10T23:51:50.000Z
Updated: 2026-11-10T23:51:50.000Z
Section: Business

> Cash, cash equivalents and marketable securities totaled $1.2 billion as of Sept. 30, 2026. Quarterly operating cash use was $44.3 million, compared with $21.6 million a year earlier.

Oruka Therapeutics, Inc. posted a third-quarter 2026 GAAP loss of $0.63 per share, matching estimates, while operating cash use rose from a year earlier.

The company had $1.2 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2026. Net cash used in operating activities totaled $44.3 million for the quarter, compared with $21.6 million in the third quarter of 2025.